TJ004309 (also known as TJD5) is a novel, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is highly immunosuppressive.   The TJ004309 IND has been cleared by the U.S. FDA and the Phase 1 trial initiated dosing in 2019 to assess safety and preliminary efficacy as a single agent and when combined with the immune checkpoint inhibitor Tecentriq® in patients with advanced solid tumors.

The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer